DD 02S
Alternative Names: DD-02SLatest Information Update: 01 Apr 2025
At a glance
- Originator D and D Pharmatech
- Class Antihyperglycaemics; Hepatoprotectants; Obesity therapies; Peptides
- Mechanism of Action Glucagon-like peptide-1 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Obesity
- No development reported Type 2 diabetes mellitus
- Discontinued Non-alcoholic steatohepatitis
Most Recent Events
- 28 Jan 2025 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in South Korea (PO)
- 18 Nov 2022 Discontinued for Non-alcoholic steatohepatitis in South Korea (PO), prior to November 2022 (D and D Pharmatech pipeline, November 2022)
- 22 Aug 2019 Early research in Non-alcoholic steatohepatitis in South Korea (PO), prior to August 2019 (D and D Pharmatech website, August 2019)